Somnomed Limited · ASX:SOM
Somnomed — Shareholder Meeting (November 2023)
16 slides from Somnomed's shareholder meeting presentation, Nov 24, 2023
Slide 1: AGM Presentation
AGM Presentation 24 November 2023 Treatment focused. Technology driven.
Slide 2: Disclaimer
Disclaimer This document has been prepared as a summary only and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This document should be read in co
Slide 3: SomnoMed’s vision and mission
SomnoMed’s vision and mission Our vision is to lead in the treatment of patients suffering from obstructive sleep apnea and relevant adjacent conditions Our mission is to advance the adoption, acceptance and treatment of oral sleep apnea therapies by medical specialists, dentists, patients and insur
Slide 4: Agenda
Agenda 1. Chair’s Address 2. CEO’s Address 3. Formal Business of Meeting 4. Closure of Meeting © November 2023 SomnoMed 4
Slide 5: Highly qualified and supportive board of directors
Highly qualified and supportive board of directors Guy Russo Michael Gordon Chairman Amrita Blickstead Non-Executive Non-Executive Highly accomplished business leader with strong commercial & Former COO & CMO for eBay Director of K Sleep Holdings customer oriented background Australia (“Koala”) a di
Slide 6: Experienced management team
Experienced management team Neil Verdal-Austin Darren Collins Mark Harding CEO CFO VP, Global Marketing 25+ years experience with Joined SomnoMed in August 2023 Joined SomnoMed in July 2019 various medical distribution and Extensive global financial Strong track record of executing manufacturing com
Slide 7: Recent Highlights
Recent Highlights Delivered revenue growth of 15% ($83.6m) and EBITDA1 of A$2.1 million Developed all necessary software and informatics systems, manufacturing quality processes and ® global marketing materials for Rest Assure commercial rollout once approvals received Initiated cost management prog
Slide 8: Solid growth profile despite tough trading conditions
Solid growth profile despite tough trading conditions • Solid revenue recovery out of COVID-19 pandemic with 13% CAGR since FY20 • Revenue and patient growth reflective of the increasing acceptance of OAT and leading brand presence of SomnoMed amongst sleep physicians and dental clinicians • Expande
Slide 9: Challenges Impacting Current Performance
Challenges Impacting Current Performance Focus Challenge Action Logistics Constrained partner delivery times from Close management of partnerships manufacturing to distribution hubs with more consistent expectations of delivery times Supply Chain Inadequate oversight across all variable inputs Dedic
Slide 10: Significant addressable markets globally
Significant addressable markets globally Obstructive sleep apnea, a growing burden on the medical system affecting a significant portion of the population Obstructive sleep apnea (OSA) is a disorder that occurs when a person’s breathing is interrupted during sleep because the airway becomes blocked
Slide 11: Growing the sector through positioning the patient’s alternative
Growing the sector through positioning the patient’s alternative Leverage One Platform and Rest Intensified efforts to position Product COAT as an effective alternative to Assure® to influence all steps Development within the patient journey and CPAP as first line therapy; and Technology provide nig
Slide 12: Rest Assure® - all night, every night data for OAT
Rest Assure® - all night, every night data for OAT Rest Assure® Addressing a key difference to CPAP SomnoMed's technology enabled oral appliance: Oral appliances have lacked overnight monitoring, unlike • Enables patients, physicians and sleep dentists to CPAP, leading to: better understand and moni
Slide 13: Rest Assure technology – how does it work?
® Rest Assure technology – how does it work? Smart oral appliance and cloud-based infrastructure SOM algorithms determine AHI1, graphs, tables Patient app Smart oral appliance with sensors recording overnight data. Physician portal Patient docks their device after Raw data transferred via night’s sl
Slide 14: Rest Assure commercial readiness
® Rest Assure commercial readiness SomnoMed’s extensive testing and operational readiness activities are de-risking the commercial rollout of Rest Assure® Delivered in FY22: Delivered in FY23: FY24 focus: ✓ Patent strategy was finalised ✓First production run of 400+ devices for ❑US 510K regulatory f
Slide 15: Strategic growth outlook
Strategic growth outlook Advance the acceptance and adoption of technology enabled OAT solution for OSA patients FY24 Guidance Operational Initiatives Strategic Objectives FY2027 aspiration2 • Revenue growth of at least • Drive medical initiative • Remain patient centric and • Over 1.5 million patie
Slide 16: For further information please contact:
For further information please contact: Corporate Investors Mr. Neil Verdal-Austin Mr. Howard Marks CEO SomnoMed Automic Group +61 406 931 477 +61 402 438 019 Nverdal-austin@somnomed.com Howard.marks@automicgroup.com.au © November 2023 SomnoMed 16